Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Centeon albumin market withdrawal costs RPR $44 mil.; consent decree allows operations to resume.

Executive Summary

CENTEON ALBUMIN RECALL COSTS RHONE-POULENC RORER $44 MIL. IN CHARGES for fiscal 1996, the French drugmaker reported Jan. 27. RPR "incurred a significant cost during the second half of the year due to the recall of Centeon's Albuminar and the cost of lost business related to other Centeon products manufactured at this facility," the company said. Centeon is the blood products joint venture of RPR and Hoechst. Centeon's Kankakee, Ill. manufacturing facility resumed production of the blood products Jan. 22 under a consent decree with FDA ("The Pink Sheet" Jan. 27, T&G-3).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029666

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel